LGVN - Longeveron spikes on long-term survival data for heart disease candidate

2023-05-09 09:26:21 ET

Clinical-stage biotech Longeveron ( NASDAQ: LGVN ) added ~15% pre-market Tuesday after announcing long-term survival data for patients who were part of the company’s ELPIS I trial for Lomecel-B in hypoplastic left heart syndrome, (HLHS).

According to data from the 10-patient open-label, Phase 1b study, all trial subjects survived and remained heart transplant-free for up to five years, an improvement from the ~20% mortality rate seen historically in HLHS children during that time.

The investigators have monitored all ten patients in ELPIS I for at least 3.5 years to date following the administration of Lomecel-B.

Noting a previous readout indicating a 100% survival rate for up to 3.5 years post Lomecel-B therapy, Joshua M. Hare, Chief Science Officer at Longeveron ( LGVN ), argued that the latest data imply additional two years of follow-up data.

Enrollment is currently underway at seven sites for the company’s ELPIS II Phase 2a trial in which 38 patients with HLHC undergoing an open heart surgery called Glenn Procedure will receive an intramyocardial injection of Lomecel-B.

More on Longeveron

• Longeveron spikes after FDA’s Fast Track Designation for lead candidate
• Longeveron Inc.: A New Approach To Treat Alzheimer's

For further details see: